Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial

BACKGROUND: Starting combination antiretroviral therapy (cART) during primary human immunodeficiency virus type 1 (HIV-1) infection results in a smaller HIV-1 latent reservoir, reduced immune activation, and less viral diversity compared to starting cART during chronic infection. We report results o...

Descripción completa

Detalles Bibliográficos
Autores principales: West, Emily, Zeeb, Marius, Grube, Christina, Kuster, Herbert, Wanner, Katrin, Scheier, Thomas, Neumann, Kathrin, Jörimann, Lisa, Hampel, Benjamin, Metzner, Karin J, Kouyos, Roger D, Braun, Dominique L, Günthard, Huldrych F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552587/
https://www.ncbi.nlm.nih.gov/pubmed/37338148
http://dx.doi.org/10.1093/cid/ciad366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552587/
https://www.ncbi.nlm.nih.gov/pubmed/37338148
http://dx.doi.org/10.1093/cid/ciad366

Ejemplares similares